Reuters logo
BRIEF-TG Therapeutics Inc gives results from phase 2 multicenter trial of TG-1101
October 26, 2017 / 11:44 AM / 23 days ago

BRIEF-TG Therapeutics Inc gives results from phase 2 multicenter trial of TG-1101

Oct 26 (Reuters) - TG Therapeutics Inc

* TG Therapeutics Inc - ‍announced results from phase 2 multicenter trial of TG-1101 (ublituximab) in relapsing forms of multiple sclerosis​

* TG Therapeutics Inc - TG-1101 was well tolerated across all patients including those receiving 1 hour infusions of phase 3 450mg dose​ Source text for Eikon: Further company coverage: ( Bangalore.newsroom@thomsonreuters.com )

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below